Royalty Pharma stock is trading -38.1% below its average target price of $46.57 after marking a 2.8% during today's afternoon session. Analysts are giving the large-cap Pharmaceutical company an average rating of buy and target prices ranging from $37.0 to $60.0 per share.
Royalty Pharma's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.6%. The stock's short ratio is 3.78. The company's insiders own 3.86% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 70.0%. In conclusion, we believe there is positive market sentiment regarding Royalty Pharma.
Institutions Invested in Royalty Pharma
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Morgan Stanley | 11% | 48,132,615 | $1,387,422,664 |
| 2023-09-30 | Vanguard Group Inc | 9% | 39,437,354 | $1,136,781,759 |
| 2023-09-30 | FMR, LLC | 7% | 30,427,172 | $877,063,256 |
| 2023-09-30 | Blackrock Inc. | 5% | 20,563,854 | $592,753,107 |
| 2023-09-30 | Baillie Gifford and Company | 4% | 18,241,284 | $525,805,025 |
| 2023-09-30 | Adage Capital Partners GP L.L.C. | 2% | 9,840,000 | $283,638,007 |
| 2023-09-30 | Viking Global Investors, L.P. | 2% | 9,464,201 | $272,805,601 |
| 2023-09-30 | JP Morgan Chase & Company | 2% | 8,887,567 | $256,184,125 |
| 2023-09-30 | State Street Corporation | 2% | 8,425,616 | $242,868,387 |
| 2023-09-30 | Geode Capital Management, LLC | 1% | 6,101,554 | $175,877,298 |
